PLPhilip William Lavori

Philip William Lavori

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Philip William Lavori has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Software for Distributed Computation on Medical Databases: A Demonstration Project

    by Balasubramanian Narasimhan, Daniel L. Rubin, Samuel M. Gross, Marina Bendersky, Philip W. Lavori

    Bringing together the information latent in distributed medical databases promises to personalize medical care by enabling reliable, stable modeling of outcomes with rich feature sets (including patient characteristics and treatments received). However, there are barriers to aggregation of medical data, due to lack of standardization of ontologies, privacy concerns, proprietary attitudes toward data, and a reluctance to give up control over end use. Aggregation of data is not always necessary for model fitting. In models based on maximizing a likelihood, the computations can be distributed, with aggregation limited to the intermediate results of calculations on local data, rather than raw data. Distributed fitting is also possible for singular value decomposition. There has been work on the technical aspects of shared computation for particular applications, but little has been published on the software needed to support the "social networking" aspect of shared computing, to reduce the barriers to collaboration. We describe a set of software tools that allow the rapid assembly of a collaborative computational project, based on the flexible and extensible R statistical software and other open source packages, that can work across a heterogeneous collection of database environments, with full transparency to allow local officials concerned with privacy protections to validate the safety of the method. We describe the principles, architecture, and successful test results for the site-stratified Cox model and rank-k Singular Value Decomposition (SVD).

  • Open Access

    Software for Distributed Computation on Medical Databases: A Demonstration Project

    by Balasubramanian Narasimhan, Daniel L. Rubin, Samuel M. Gross, Marina Bendersky, Philip W. Lavori

    Software for Distributed Computation on Medical Databases: A Demonstration Project


  • Integrating Randomized Comparative Effectiveness Research with Patient Care

    by Louis D. Fiore, Philip W. Lavori

    Clinical trials that are embedded into usual care have the potential to yield outcomes of great relevance to the institutions where they are performed and at the same time to yield information that may be generalizable to the health care system at large. In this article, we review four clinical trials that were conducted in three health care systems using their extant electronic health record (EHR) systems. We find that EHR-based clinical trials are feasible but pose limitations on the questions that can be addressed, the processes that can be implemented, and the outcomes that can be assessed. We think that the current requirements for ethics review should be reconsidered for such trials, in which the risk for participants that can be attributed to research is low.


  • Introduction to dynamic treatment strategies and sequential multiple assignment randomization

    by Philip W Lavori, Ree Dawson

    Background: In June 2013, a 1-day workshop on Dynamic Treatment Strategies (DTSs) and Sequential Multiple Assignment Randomized Trials (SMARTs) was held at the University of Pennsylvania in Philadelphia, Pennsylvania. These two linked topics have generated a great deal of interest as researchers have recognized the importance of comparing entire strategies for managing chronic disease. A number of articles emerged from that workshop. Purpose: The purpose of this survey of the DTS/SMART methodology (which is taken from the introductory talk in the workshop) is to provide the reader the collected articles presented in this volume with sufficient background to appreciate the more detailed discussions in the articles. Methods: The way that the DTS arises naturally in clinical practice is described, along with its connection to the well-known difficulties of interpreting the analysis by intention-to-treat. The SMART methodology for comparing DTS is described, and the basics of estimation and inference presented. Results: The DTS/SMART methodology can be a flexible and practical way to optimize ongoing clinical decision making, providing evidence (based on randomization) for comparative effectiveness. Limitations: The DTS/SMART methodology is not a solution for unstandardized study protocols. Conclusions: The DTS/SMART methodology has growing relevance to comparative effectiveness research and the needs of the learning healthcare system.


  • Open Access

    Translating the Diabetes Prevention Program Lifestyle Intervention for Weight Loss Into Primary Care

    by Jun Ma, Veronica Yank, Lan Xiao, Philip W. Lavori, Sandra R. Wilson, Lisa G. Rosas, Randall S. Stafford

    An estimated 69% of US adults are overweight or obese,1 and those with modifiable cardiometabolic risk factors are a critical target group for intervention.2,3 Lifestyle modification focused on modest (5%-10%) weight loss and moderate-intensity physical activity can significantly reduce the incidence of type 2 diabetes mellitus (DM) (as much as 58% as shown in the Diabetes Prevention Program [DPP]) and cardiometabolic risk factors in high-risk individuals,4-6 with benefits sustained for at least 10 years.7 Evidence-based guidelines therefore recommend effective lifestyle intervention for weight management and disease prevention.8,9


  • Adaptive Trial Designs

    by Tze Leung Lai, Philip William Lavori, Mei-Chiung Shih

    We review adaptive designs for clinical trials, giving special attention to the control of the Type I error in late-phase confirmatory trials, when the trial planner wishes to adjust the final sample size of the study in response to an unblinded analysis of interim estimates of treatment effects. We point out that there is considerable inefficiency in using the adaptive designs that employ conditional power calculations to reestimate the sample size and that maintain the Type I error by using certain weighted test statistics. Although these adaptive designs have little advantage over familiar group-sequential designs, our review also describes recent developments in adaptive designs that are both flexible and efficient. We also discuss the use of Bayesian designs, when the context of use demands control over operating characteristics (Type I and II errors) and correction of the bias of estimated treatment effects.


  • Open Access

    Innovative Clinical Trial Designs

    by Tze L. Lai, Philip W. Lavori


  • Open Access

    The Breathe Easier through Weight Loss Lifestyle (BE WELL) Intervention: A randomized controlled trial

    by Jun Ma, Peg Strub, Carlos A CamargoJr, Lan Xiao, Estela Ayala, Christopher D Gardner, A Sonia Buist, William L Haskell, Phillip W Lavori, Sandra R Wilson

    Obesity and asthma have reached epidemic proportions in the US. Their concurrent rise over the last 30 years suggests that they may be connected. Numerous observational studies support a temporally-correct, dose-response relationship between body mass index (BMI) and incident asthma. Weight loss, either induced by surgery or caloric restriction, has been reported to improve asthma symptoms and lung function. Due to methodological shortcomings of previous studies, however, well-controlled trials are needed to investigate the efficacy of weight loss strategies to improve asthma control in obese individuals. BE WELL is a 2-arm parallel randomized clinical trial (RCT) of the efficacy of an evidence-based, comprehensive, behavioral weight loss intervention, focusing on diet, physical activity, and behavioral therapy, as adjunct therapy to usual care in the management of asthma in obese adults. Trial participants (n = 324) are patients aged 18 to 70 years who have suboptimally controlled, persistent asthma, BMI between 30.0 and 44.9 kg/m2, and who do not have serious comorbidities (e.g., diabetes, heart disease, stroke). The 12-month weight loss intervention to be studied is based on the principles of the highly successful Diabetes Prevention Program lifestyle intervention. Intervention participants will attend 13 weekly group sessions over a four-month period, followed by two monthly individual sessions, and will then receive individualized counseling primarily by phone, at least bi-monthly, for the remainder of the intervention. Follow-up assessment will occur at six and 12 months. The primary outcome variable is the overall score on the Juniper Asthma Control Questionnaire measured at 12 months. Secondary outcomes include lung function, asthma-specific and general quality of life, asthma medication use, asthma-related and total health care utilization. Potential mediators (e.g., weight loss and change in physical activity level and nutrient intake) and moderators (e.g., socio-demographic characteristics and comorbidities) of the intervention effects also will be examined. This RCT holds considerable potential for illuminating the nature of the obesity-asthma relationship and advancing current guidelines for treating obese adults with asthma, which may lead to reduced morbidity and mortality related to the comorbidity of the two disorders. NCT00901095


  • Missing Data in Longitudinal Clinical Trials Part A: Design and Conceptual Issues

    by Philip W. Lavori, C. Hendricks Brown, Naihua Duan, Robert D. Gibbons, Joel Greenhouse

    There are numerous types of missing data that can occur in clinical trials. Some types of missing data cannot be prevented and are beyond the research team’s control. For example, a patient may relocate and be unavailable for an assessment. Other types occur because the research team actually designs the study to generate incomplete data. For example, it may not be cost-effective to obtain a full diagnostic assessment on each subject. Instead, an inexpensive screening tool is used to assess everyone. All screen positives, plus a random sample of screen negatives, are then given the full diagnostic. The incomplete diagnostic data on the majority of those screened negative are taken into account in assessing treatment effects.1-3 These types of data are missing by design, and there are statistical procedures to handle such planned missing data if designed appropriately. The third type occurs because of a faulty design plan by the research team. In this case, data are lost because a less than adequate protocol is followed. For example, if no screen negatives are given the full diagnostic, it will not be possible to ascertain the false negatives. ABOUT THE AUTHORS Philip W. Lavori, PhD, is Professor of Biostatistics, and Chair, Department of Health Research and Policy, Stanford University School of Medicine. C. Hendricks Brown, PhD, is with the Prevention Science and Methodology Group, Departments of Epidemiology and Biostatistics, College of Public Health, University of South Florida, Tampa. Naihua Duan, PhD, is Professor of Biostatistics in Psychiatry, Departments of Biostatistics and Psychiatry, Columbia University, New York; and Director, Division of Biostatistics, N.Y. Psychiatric Institute. Robert D. Gibbons, PhD, is Professor of Biostatistics and Psychiatry, and Director of the Center for Health Statistics, University of Illinois at Chicago. Joel Greenhouse, PhD, is with the Department of Statistics, Carnegie Mellon University, Pittsburgh. Address correspondence to: Philip Lavori, HRP/Redwood Building, 259 Campus Drive, Stanford, CA 94305-5405; fax 650-725-6951; or e-mail lavori@stanford.edu. Dr. Lavori, Dr. Brown, Dr. Duan, Dr. Gibbons, and Dr. Greenhouse have disclosed no relevant financial relationships. EDUCATIONAL OBJECTIVES Describe problems associated with missing data in psychiatric research. Define how missing data can be minimized by improved experimental designs. Identify methods that should be avoided when analyzing studies with missing data.